IndEx-2: Assessing the impact of antigen density on the safety and efficacy of bispecifics
- A stable cell platform to precisely control target antigen expression over physiologically relevant expression levels, modelling healthy and disease states
- Orthogonal control of two target antigens in the same cell line to characterise single and dual-targeted therapeutics
- Integrated with real-time cytotoxicity, flow cytometry, and cytokine assays to select therapeutics with optimal characteristics by determining activation thresholds and informing therapeutic index, illustrated in a case study comparing a CD19-directed T cell engager CLN-978 vs. Blinatumomab